Company news

Radiopharm Theranostics Limited news in 2022

Radiopharm Theranostics Limited's news releases, calls and decks from 2022, newest first.

View company

aVb6 Integrin (RAD301) IND approval for Phase 1 trial

December 29, 2022

Security Class Reinstatement to Quotation

November 27, 2022

Security Class Suspension from Quotation RADO

November 20, 2022

Entitlement Offer - Extension of Retail Offer

November 8, 2022

RAD agreement with NorthStar for supply of Actinium-225

October 25, 2022

Successful Completion of Institutional Entitlement Offer

October 19, 2022

Entitlement Offer to raise up to $10 million

October 19, 2022

Pivalate achieves positive Phase 2 data in brain mets trial

October 18, 2022

Presentation - Pivalate achieves positive Phase 2 data

October 18, 2022

Suspension from Official Quotation

October 16, 2022

FDA grants rare pediatric disease designation for DUNP19

September 16, 2022

FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma

September 8, 2022

RAD Licenses UCLA Dual Action Antibody

April 3, 2022

LOI with GenesisCare to start first trial in Australia

March 23, 2022

Radiopharm and TerraPower sign Actinium 225 agreement

January 31, 2022

RAD acquires IP Ownership of Radiopharmaceutical Nanobodies

January 23, 2022

Decks in 2022